Neil Brewis
Chief Executive Officer bij F-STAR THERAPEUTICS, INC.
Profiel
Neil Brewis is currently a Director at F-star Therapeutics Ltd.
He is also a Director, Chief Executive & Scientific Officer at F-star Therapeutics, Inc. since 2023.
In addition, he holds the position of Chief Scientific Officer at F-star Alpha Ltd.
since 2015.
Previously, Dr. Brewis worked as the Head-Research at Domantis Ltd.
from 2002 to 2007.
He then served as the Vice President & Head-Biopharmaceuticals Research at GSK Plc from 2007 to 2015.
He also held the position of Chief Scientific Officer at F-Star Therapeutics, Inc. (United States).
Dr. Brewis obtained a doctorate degree from the University Of Dundee and an undergraduate degree from the University of Hertfordshire.
Actieve functies van Neil Brewis
Bedrijven | Functie | Begin |
---|---|---|
F-STAR THERAPEUTICS, INC. | Chief Executive Officer | - |
F-star Alpha Ltd.
F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | Chief Tech/Sci/R&D Officer | 02-11-2015 |
F-star Therapeutics Ltd.
F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | - |
Eerdere bekende functies van Neil Brewis
Bedrijven | Functie | Einde |
---|---|---|
GSK PLC | Corporate Officer/Principal | 01-10-2015 |
Domantis Ltd.
Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | Chief Tech/Sci/R&D Officer | 01-01-2007 |
SPRING BANK PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Neil Brewis
University Of Dundee | Doctorate Degree |
University of Hertfordshire | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
GSK PLC | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Domantis Ltd.
Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | Health Technology |
F-Star Therapeutics, Inc. (United States)
F-Star Therapeutics, Inc. (United States) Pharmaceuticals: MajorHealth Technology F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA. | Health Technology |
F-star Alpha Ltd.
F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
F-star Therapeutics Ltd.
F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
F-star Therapeutics, Inc.
F-star Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom. | Health Technology |